Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics
Crossref DOI link: https://doi.org/10.1007/s12272-016-0719-7
Published Online: 2016-02-19
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kim, Mi-Gyeong
Kim, Dongyoon
Suh, Soo-Kyung
Park, Zewon
Choi, Min Joung
Oh, Yu-Kyoung
Funding for this research was provided by:
Ministry of Food and Drug Safety (15172MFDS163)
Text and Data Mining valid from 2016-02-19